212 related articles for article (PubMed ID: 27371102)
1. Costs of introducing pneumococcal, rotavirus and a second dose of measles vaccine into the Zambian immunisation programme: Are expansions sustainable?
Griffiths UK; Bozzani FM; Chansa C; Kinghorn A; Kalesha-Masumbu P; Rudd C; Chilengi R; Brenzel L; Schutte C
Vaccine; 2016 Jul; 34(35):4213-4220. PubMed ID: 27371102
[TBL] [Abstract][Full Text] [Related]
2. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
[TBL] [Abstract][Full Text] [Related]
3. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi.
Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F
Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006
[TBL] [Abstract][Full Text] [Related]
4. Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions.
Usuf E; Mackenzie G; Lowe-Jallow Y; Boye B; Atherly D; Suraratdecha C; Griffiths UK
Vaccine; 2014 Apr; 32(17):1975-81. PubMed ID: 24503271
[TBL] [Abstract][Full Text] [Related]
5. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.
Ojal J; Griffiths U; Hammitt LL; Adetifa I; Akech D; Tabu C; Scott JAG; Flasche S
Lancet Glob Health; 2019 May; 7(5):e644-e654. PubMed ID: 31000132
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
7. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines.
De la Hoz-Restrepo F; Castañeda-Orjuela C; Paternina A; Alvis-Guzman N
Vaccine; 2013 Jul; 31 Suppl 3():C80-7. PubMed ID: 23777697
[TBL] [Abstract][Full Text] [Related]
10. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Constenla D; Liu T
Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
[TBL] [Abstract][Full Text] [Related]
11. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
12. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.
Clark A; Jauregui B; Griffiths U; Janusz CB; Bolaños-Sierra B; Hajjeh R; Andrus JK; Sanderson C
Vaccine; 2013 Jul; 31 Suppl 3():C19-29. PubMed ID: 23777686
[TBL] [Abstract][Full Text] [Related]
13. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of routine immunisation in Zambia.
Schütte C; Chansa C; Marinda E; Guthrie TA; Banda S; Nombewu Z; Motlogelwa K; Lervik M; Brenzel L; Kinghorn A
Vaccine; 2015 May; 33 Suppl 1():A47-52. PubMed ID: 25919174
[TBL] [Abstract][Full Text] [Related]
15. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
16. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
[TBL] [Abstract][Full Text] [Related]
17. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
[TBL] [Abstract][Full Text] [Related]
20. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
